Logo

Cofactor Genomics Pinnacle Assay

Feb 16, 2017

Cofactor Genomics has launched Pinnacle, an RNA-based oncology assay which provides insights into a patient's cancer profile. The assay reports on both aberrant oncology-relevant gene expression and known cancer gene fusions detected in the tumor sample. It uses the company's software to compare each patient's cancer expression profile to Cofactor's database of thousands of expression profiles from the same cancer type, the company said. Pinnacle is currently approved for use with formalin-fixed, paraffin-embedded tumor tissue.

Breaking News
The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.